Boehringer Ingelheim invest 55 million eur in China

30 May 2012 - Taizhou, China, and Ingelheim, Germany  Today the research based pharmaceutical company Boehringer Ingelheim and Taizhou China Medical City in Jiangsu Province, China, announced the signing of an agreement for the establishment of a veterinary vaccine manufacturing plant. Under the terms of the agreement, the plant will be built in Taizhou China Medical City, a national pharmaceutical high-tech industry park (250 kms North of Shanghai). The total investment will be more than 55.5 million euro.